Hester Biosciences Limited — Updates, 09-05-2025: Press Release

Hester Biosciences has announced a board meeting on dividend declaration and the financial results for the quarter and half-year. Standalone product sales grew 12% in FY25, driven by 6% growth in Animal Healthcare and 16% in Poultry Healthcare. Profit increased 17% for FY25 and 30% in Q4, aided by cost efficiencies and improved product mix. Consolidated sales rose 13% with net profit up 36% in FY25, though Q4 PAT declined due to subsidiary volatility. Subsidiaries in Nepal and Africa showed gains with new vaccine approvals and tenders. Plans include launching an Avian Influenza vaccine and expanding feed supplements, focusing on Africa.